SI
PCRX icon

Standard Investments’s Pacira BioSciences PCRX Stock Holding History

Standard Investments’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-399,496
Closed -$15M – 9
2017
Q3 		$15M Hold
399,496
– – 3.16% 8
2017
Q2 		$19.1M Hold
399,496
– – 2.73% 11
2017
Q1 		$18.2M Sell
399,496
-375,892
-48% -$16.2M 2.5% 11
2016
Q4 		$25M Hold
775,388
– – 4.58% 6
2016
Q3 		$26.5M Hold
775,388
– – 4.84% 6
2016
Q2 		$26.2M Sell
775,388
-32,262
-4% -$1.59M 3.55% 7
2016
Q1 		$42.8M Buy
807,650
+67,650
+9% +$3.96M 4.27% 8
2015
Q4 		$56.8M Buy
740,000
+30,000
+4% +$1.7M 3.97% 7
2015
Q3 		$29.2M Buy
710,000
+279,465
+65% +$17.1M 2.06% 11
2015
Q2 		$30.4M Buy
430,535
+148,251
+53% +$11.7M 1.72% 13
2015
Q1 		$25.1M Buy
282,284
+267,032
+1,751% +$27.1M 1.54% 13
2014
Q4 		$1.35M Buy
15,252
+9,520
+166% +$900K 0.07% 108
2014
Q3 		$556K Hold
5,732
– – 0.03% 161
2014
Q2 		$527K Sell
5,732
-6,634
-54% -$505K 0.03% 149
2014
Q1 		$865K Buy
12,366
+3,206
+35% +$218K 0.08% 136
2013
Q4 		$527K Buy
+9,160
New +$482K 0.04% 133

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Standard Investments's PCRX Position: Q4 2017 in Review

Standard Investments sold out of Pacira BioSciences (PCRX) in Q4 2017, closing a stake of 399,496 shares — an estimated $15M sold.

Standard Investments first reported a position in PCRX in Q4 2013 and held it in 16 quarters. The position peaked at $56.8M in Q4 2015. 185 funds tracked by Wall St. Rank hold PCRX as of Q4 2017.

  • Standard Investments reported no remaining Pacira BioSciences position as of Q4 2017 after selling out during the quarter.
  • Standard Investments sold 399,496 Pacira BioSciences shares in Q4 2017, an estimated $15M.
  • Standard Investments first reported a position in Pacira BioSciences in Q4 2013 and held it in 16 quarters.
  • Standard Investments's Pacira BioSciences position peaked at $56.8M in Q4 2015.
  • 185 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2017.

Based on Standard Investments's 13F filing for Q4 2017, filed 14 Feb 2018.